Moderna to complete US mRNA manufacturing network with $140 million investment

Core Insights - Moderna announced it will now operate full end-to-end manufacturing for its mRNA medicines in the U.S., which is a significant advancement in enhancing the company's domestic production capabilities [1] Group 1 - The decision to establish full end-to-end manufacturing indicates a strategic move to strengthen the domestic production network [1]